Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Pioglitazone for Secondary Prevention After Stroke (IRIS)
NCT00091949Phase 3Completed
- Sponsor
- Yale University
- Start
- Feb 2005
- Primary completion
- Nov 2015
- Modality
- Small Molecules
- Countries
- 8
01
Overview
Phase 3, randomised, double-blind trial of pioglitazone in stroke and myocardial infarction (MI), sponsored by Yale University. Primary endpoint: Recurrent Fatal or Non-fatal Stroke, or Fatal or Non-fatal Myocardial Infarction at 5 years. Started Feb 2005; status: completed.
02
Drugs
pioglitazone
03
Conditions
strokemyocardial infarction (MI)
Beyond the preview
Go deeper on NCT00091949.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00091949.